| Literature DB >> 28303024 |
Wen Jiang1, Hengfeng Yuan2,3, Charles K Chan4, Christina A von Roemeling3, Zuoqin Yan2, Irving L Weissman4,5, Betty Y S Kim3,6,7.
Abstract
Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.Entities:
Mesh：
Year: 2017 PMID： 28303024 DOI： 10.1038/nrd.2017.34
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694